TGV-inhalonix is dedicated to the development of inhaled Mul-1867 to treat lung infections in cystic fibrosis patients. As a research-based and innovation-driven company, we devote our science to deepening the understanding of pathological processes and uncovering new approaches to the development of life-saving drugs. We believe that we can best achieve these goals together with partners who can supplement and complement our strengths and capabilities.
TGV-inhalonix has successful partnerships involving companies, funds and academic institutions. Here are some examples of our partnerships.